Article Per Year (5 Year)
p-Index From 2020 - 2025
0.408
P-Index
This Author published in this journals
All Journal Jurnal Respirasi (JR) Indonesian Journal of Cancer
Hanif, Muhammad Alfin
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Medicine & Pharmacology Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Diagnostic Accuracy of Modalities for Diagnosis of Thoracic Cancer: Retrospective Analysis Ariawan, Wily Pandu; Hanafi, Arif Riswahyudi; Pradipta, Jaka; Jayusman, Mulawarman; Hanif, Muhammad Alfin; Hutabarat, Jubillete Windy; Amira, Salsabila Nur
Indonesian Journal of Cancer Vol 19, No 3 (2025): September
Publisher : http://dharmais.co.id/

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v19i3.1307

Abstract

Background: Thoracic cancer becomes a huge consideration, especially for lung cancer, because it quietly increases over time and needs highly sensitive diagnostic modalities. Thus, we aim to investigate the diagnostic accuracy of several cytology-based modalities to diagnose thoracic cancer. It would serve as a reference for other cancer centers in estimating diagnostic approaches for thoracic cancer.Method: Retrospective analysis with a cross-sectional study comprised of 2358 diagnostic procedures at Dharmais Cancer Hospital, Jakarta, Indonesia, from 2020 to 2023. Data were extracted from e-medical records. We compared seven cytology-based procedures to the gold standard, which is histopathology examination. Results: Study subjects (n=2358; mean age 60 ± 12.0; 62.6% male) predominantly used the mode of diagnostic Bronchial Brushing Cytology (BBC) about 676 (28.7%). Endobronchial Ultrasound (EBUS) was the highest sensitivity (88.1%) of the diagnostic approach for thoracic cancer (p 0.05).Conclusion: EBUS had the highest sensitivity in diagnosing thoracic cancer. However, multimodality diagnostic procedures should be considered for patients who have symptoms suggestive of thoracic cancer to get highly positive results and lower complications, both cytologically and histologically. As a national cancer center, providing data on diagnostic modalities is necessary, and an analysis of cancer services is required for informed policy recommendations.
The Time to Progression in Lung Adenocarcinoma Patients Receiving First- and Second-Generation EGFR-TKI in Indonesia Syahruddin, Elisna; Soeroso, Noni Novisari; Ananda, Fannie Rizki; Wulandari, Laksmi; Setijadi, Ana Rima; Ermayanti, Sabrina; Pratiwi, Suryanti Dwi; Infianto, Andreas; Andayani, Novita; Munir, Sri Melati; Pratama, Avissena Dutha; Kusumawardani, Ida Ayu Jasminarti Dwi; Haryati, Haryati; Duyen, Natalie; Hanif, Muhammad Alfin; Lim, Darren Wan-Teck
Jurnal Respirasi Vol. 11 No. 1 (2025): January 2025
Publisher : Faculty of Medicine Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/jr.v11-I.1.2025.22-30

Abstract

Introduction: Targeted therapy, particularly epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), is the first-line treatment for non-small cell lung cancer (NSCLC). However, drug resistance has grown in the last few decades. This study compared the progression time of lung cancer patients treated with first- and second-generation EGFR-TKI. Methods: Based on cytology and histological results, this cross-sectional study included 1,008 participants diagnosed with lung adenocarcinoma (LUAD) from 11 Indonesian Respiratory Centers. Every three months, the response to treatment was assessed using the Response Evaluation Criteria in Solid Tumours (RECIST) criteria in 1.1. Significant differences in the clinical features of the three TKI treatment groups were identified using logistic regression analysis, the median time to disease progression was estimated using the Kaplan-Meier technique, and independent prognostic factors related to the time to progression (TTP) were assessed using Cox proportional hazards regression. Results: This study examined 505 patients, the majority of whom were females (50.9%), never smoked (59.8%), diagnosed at an advanced stage (99.2%), and had an Eastern Cooperative Oncology Group (ECOG) scale of 0-1 (83.2%). Approximately 98.1% of patients were treated with afatinib (14.8%), erlotinib (18.6%), and gefitinib (66.1%) due to common mutations. The groups did not differ significantly (p>0.05). The median overall survival (OS) rate was 9 months. The time to LUAD progression in lung cancer was significantly impacted by poor performance (p=0.001). Conclusion: Epidermal growth factor receptor-tyrosine kinase inhibitor treatment can only prolong the TTP of LUAD by up to 9 months, and the performance scale when receiving the EGFR-TKI significantly affects the prognosis.
Co-Authors Amira, Salsabila Nur Ana Rima Setijadi Ananda, Fannie Rizki Ariawan, Wily Pandu Duyen, Natalie Elisna Syahruddin Ermayanti, Sabrina Hanafi, Arif Riswahyudi Haryati Haryati Hutabarat, Jubillete Windy Ida Ayu Jasminarti Dwi Kusumawardani Infianto, Andreas Jayusman, Mulawarman Laksmi Wulandari Lim, Darren Wan-Teck Noni Novisari Soeroso Novita Andayani, Novita Pradipta, Jaka Pratama, Avissena Dutha Pratiwi, Suryanti Dwi Sri Melati Munir